Patterns of Warfarin Use in Subgroups of Patients with Atrial Fibrillation: A Cross-Sectional Analysis of 430 General Practices in the United Kingdom

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Mohammed, Mohammed A ^a   Marshall, Tom ^a   Nirantharakumar, Krishnarajah ^a   Stevens, Andrew ^a   Fitzmaurice, David ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

AGE; AGED; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMENTIA; DRUG USE; FEMALE; GENERAL PRACTICE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RETROSPECTIVE STUDY; SEX DIFFERENCE; UNITED KINGDOM;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; FEMALE; GENERAL PRACTICE; GREAT BRITAIN; GUIDELINE ADHERENCE; HUMANS; MALE; RISK; WARFARIN;

EID: 84877035351     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061979     Document Type: Article

References (40)

1. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, et al. (1994) Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). American Journal of Cardiology 74: 236-41.
2. Lip GYH, Yse HF, Lane DA, (2012) Atrial fibrillation Lancet. 379: 648-61.
3. Dewilde S, Carey IM, Emmas C, Richards N, Cook DG, (2006) Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 92(8): 1064-70 Epub 2005 Dec 30.
4. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, et al. (2006) Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). European Heart Journal 27(16): 1979-2030.
5. Kannel WB, Abbott RD, Savage DD, McNamara PM, (1982) Epidemiologic features of chronic atrial fibrillation: the Framingham study. New England Journal of Medicine 306: 1018-22.
6. Stewart S, Hart CL, Hole DJ, McMurray JJ, (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. American Journal of Medicine 113: 359-64.
7. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, et al. (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98(10): 946-52.
8. Kammersgaard LP, Olsen TS, (2006) Cardiovascular risk factors and 5-year mortality in the Copenhagen Stroke Study Cerebrovascular Diseases. 21(3): 187-93.
9. Atrial Fibrillation (2006) National Clinical Guideline for Management in Primary and Secondary Care. Royal College of Physicians.
10. Wolf PA, Abbott RD, Kannel WB, (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22(8): 983-988.
11. Antithrombotic Trialists' Collaboration Collaborative (2002) Meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86.
12. Aguilar MI, Hart R (2005) Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD001927. DOI: 10.1002/14651858.CD001927.pub2.
13. Aguilar MI, Hart R, Pearce LA (2007) Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD006186. DOI: 10.1002/14651858.CD006186.pub2.
14. Havard J, (2009) Why are we so bad in primary care at initiating warfarin in atrial fibrillation patients? The British Journal of Cardiology 16: 237-40.
15. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, et al. (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370: 493-503.
16. National Collaborating Centre for Chronic Conditions (2006) Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London: Royal College of Physicians.
17. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, et al. (2008) Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest; 133(6 Suppl):546S-92S.
18. European Heart Rhythm Association European Association for Cardio-Thoracic Surgery (2010) Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, et al. (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal 31(19): 2369-429 Epub 2010 Aug 29.
19. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, et al. (2009) The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 151: 297-305.
20. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, et al. (2011) ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol;15 57(11): e101-98.
21. Guidelines for the management of atrial fibrillation (2010) The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Guidelines for the management of atrial fibrillation. European Heart Journal 31: 2369-429 Available from www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-afib-FT.pdf.
22. NICE Clinical Guideline 36 (2006) Atrial fibrillation. The management of atrial fibrillation. Available: http://www.nice.org.uk/nicemedia/live/10982/30052/30052.pdf. Accessed 2012 Jun.
23. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY, (2010) Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123(7): 638-645.e4.
24. Meiltz A, Zimmermann M, Urban P, Bloch A, (2008) Association of Cardiologists of the Canton of Geneva. Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace 10: 674-680.
25. Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, et al. (2011) Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol 100(10): 897-905.
26. Maguire A, Blak BT, Thompson M, (2009) The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiology and Drug Safety 18(1): 76-83.
27. British National Formulary BMJ Group and the Royal Pharmaceutical Society of Great Britain (2011) Available: http://bnf.org/bnf/index.htm.Accessed 2012 Jan 5.
28. Baczek V, Chen WT, Kluger J, Coleman CI, (2012) Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Family Practice:13 5: 5 Doi:10.1186/1471-2296-13-5.
29. Breiman L, Friedman JH, Olshen RA, Stone CJ (1984) Classification and regression trees. Monterey CA: Wadsworth & Brooks/Cole Advanced Books & Software.
30. Steyerberg EW (2009) Clinical Prediction Models. A practical approach to development, validation and updating.
31. Harper PR, (2005) A review and comparison of classification algorithms for medical decision making. Health Policy 71: 315-31.
32. Podgorelec V, Kokol P, Stiglic B, Rozman I, (2002) Decision trees: An Overview and Their Use in Medicine. J Med Syst 26(5): 455-63.
33. Hothorn T, Hornik K, Zeileis A, (2006) Unbiased Recursive Partitioning: A Conditional Inference Framework. J Comput Graph Stat 15(3): 651-674.
34. R Development Core Team (2011) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available: http://www.R-project.org.
35. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, et al. (2010) Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal 31(19): 2369-429.
36. Baczek VL, Chen WT, Kluger J, Coleman CI (2012) Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Family Practice;3;13.
37. Gattellari (2010) Barriers to the Use of Anticoagulation for Nonvalvular Atrial Fibrillation: A Representative Survey of Australian Family Physicians (vol 25, pg 1750, 2003). Stroke 41(4): E398.
38. Stein PD, Goldman J, (2009) Obesity and Thromboembolic Disease. Clinics in Chest Medicine 30(3): 489.
39. Klein I, Danzi S, (2007) Thyroid disease and the heart. Circulation; 9 116(15): 1725-3.
40. Lip GY, Frison L, Halperin JL, Lane DA, (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 11 57(2): 173-80 Epub 2010 Nov 24. PubMed PMID: 21111555.